Highlights Moberg Pharma AB

Equities

MOB

SE0020353928

Market Closed - Nasdaq Stockholm Other stock markets 11:29:38 2024-05-29 am EDT			5-day change	1st Jan Change
24.3 ^SEK	-4.03%		-7.95%	+59.87%

May. 14	Moberg Pharma AB Elects Jonas Ekblom as Board Member	CI
May. 07	Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure	May. 06	CI
Moberg Pharma AB Announces Launch Update for Mob-015	Apr. 23	CI
Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	Apr. 08	CI
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
Moberg Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Moberg Pharma Completes Patient Recruitment for North American Trial of Nail Fungus Treatment	23-10-06	MT
Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America	23-10-06	CI
Rights Issue: 16 new shares @ 5.75 SEK for 9 existing shares	23-08-10	FA
Rights Issue: 16 new shares @ 5.75 SEK for 9 existing shares	23-08-10	FA
Moberg Pharma AB Announces National Approval for MOB-015 in Sweden	23-08-04	CI
Moberg Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Moberg Pharma AB Announces That Mob-015 has Received National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults	23-07-31	CI
Cipher Pharmaceuticals Partner, Moberg Pharma, Announces Approval for MOB-015 in the European Union	23-07-05	MT
Cipher Pharmaceuticals Brief: Partner, Moberg Pharma Announcing Approval for MOB-015 in the European Union	23-07-05	MT
Moberg Pharma AB Announces Approval for Mob-015 in the European Union	23-07-05	CI
Moberg Pharma's Antifungal Medicine Backed for Approval in 13 EU Nations; Shares Tank 39%	23-06-28	MT
Moberg Pharma AB Recommends for Approval in EU	23-06-28	CI
Reverse Split: 1 of 10	23-05-23	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Moberg Pharma AB

Equities

MOB

SE0020353928

Highlights

Filters